SCHEMBL16640348

SCHEMBL16640348

CC(C)c1ccc(-n2c3ccccc3c3ncccc32)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.41
KDM4E B2RXH2 2/20 0.41
ATM Q13315 1/20 0.41
TRPV4 Q9HBA0 1/20 0.38
REN P00797 1/20 0.38
KMT2A Q03164 1/20 0.37
PDE4A P27815 2/20 0.36
PDE4B Q07343 2/20 0.36
PDE4C Q08493 2/20 0.36
PDE4D Q08499 2/20 0.36
NOTUM Q6P988 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
NPC1 O15118 2/20 0.36
HSP90AA1 P07900 1/20 0.36
MAPT P10636 3/20 0.36
TP53 P04637 1/20 0.36
PTPN1 P18031 1/20 0.36
IDO1 P14902 1/20 0.35
DHODH Q02127 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12383087 0.86 RXFP1 (0.47) L3MBTL1KDM4EATMRENKMT2A
SCHEMBL20172101 0.85 KDM4E (0.41) L3MBTL1KDM4EATMRENKMT2A
SCHEMBL11978685 0.83 ALDH1A1 (0.47) L3MBTL1KDM4EATMKMT2ATDP1
SCHEMBL13141973 0.83 KDM4E (0.47) L3MBTL1KDM4EATMPDE4APDE4B
SCHEMBL261831 0.83 KDM4E (0.47) L3MBTL1KDM4EATMPDE4APDE4B
SCHEMBL12396559 0.82 L3MBTL1 (0.61) L3MBTL1KDM4EATMRENPDE4A
SCHEMBL16640318 0.82 PDE4A (0.41) L3MBTL1KDM4EATMKMT2APDE4A
SCHEMBL1102414 0.82 KDM4E (0.59) L3MBTL1KDM4EATMTRPV4KMT2A
SCHEMBL16640329 0.82 HTT (0.35) L3MBTL1KDM4EATMRENKMT2A
SCHEMBL16640319 0.82 GRM4 (0.35) L3MBTL1KDM4EATMRENTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11189808-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2021-11-30 US disclosed
US-20200152891-A1 PLATINUM COMPLEXES AND DEVICES UNIV ARIZONA STATE (US) 2020-05-14 US disclosed
US-9947881-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-04-17 US disclosed
US-9947881-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-04-17 US disclosed
US-20170012224-A1 PLATINUM COMPLEXES AND DEVICES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2017-01-12 US disclosed
US-9385329-B2 Platinum complexes and devices Arizona Board of Regents on behalf of Arizona State University and Universal Display Corporation (US) 2016-07-05 US disclosed
US-9385329-B2 Platinum complexes and devices Arizona Board of Regents on behalf of Arizona State University and Universal Display Corporation (US) 2016-07-05 US disclosed
US-20150105556-A1 PLATINUM COMPLEXES AND DEVICES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2015-04-16 US disclosed
US-20150105556-A1 PLATINUM COMPLEXES AND DEVICES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11189808-B2 Platinum complexes and devices OXA1L, OCIAD1, OCIAD2 L3MBTL1 1502/4885KDM4E 4835/4885ATM 1739/4885
US-20200152891-A1 PLATINUM COMPLEXES AND DEVICES OXA1L, OCIAD1, OCIAD2 L3MBTL1 1502/4885KDM4E 4835/4885ATM 1739/4885
US-20170012224-A1 PLATINUM COMPLEXES AND DEVICES OXA1L, OCIAD1, OCIAD2 L3MBTL1 1502/4885KDM4E 4835/4885ATM 1739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.